Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial

Etavopivat (FT‐4202) is an orally administered, small‐molecule allosteric activator of erythrocyte pyruvate kinase‐R (PKR) in clinical development for the treatment of sickle cell disease and other hemoglobin disorders. This randomized, placebo‐controlled, double‐blind, first‐in‐human combination si...

Descripción completa

Detalles Bibliográficos
Autores principales: Forsyth, Sanjeev, Schroeder, Patricia, Geib, James, Vrishabhendra, Leela, Konstantinidis, Diamantis G., LaSalvia, Kari, Ribadeneira, Maria D., Wu, Eric, Kelly, Patrick, Kalfa, Theodosia A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306898/
https://www.ncbi.nlm.nih.gov/pubmed/35019238
http://dx.doi.org/10.1002/cpdd.1058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306898/
https://www.ncbi.nlm.nih.gov/pubmed/35019238
http://dx.doi.org/10.1002/cpdd.1058

Ejemplares similares